The subscription period in the Rights Issue ended on April 22, 2021. The final outcome shows that a total of 6,962,407 units have been subscribed for through the Rights Issue and the Company will thus receive approximately MSEK 56.4 before issue costs. Upon full exercise of all warrants series 2021/2023, the Company may be provided with an additional capital injection of up to approximately SEK 85 million after the exercise period that runs from and including March 23, 2023 to and including April 5, 2023.

Allocation of units subscribed for without the support of unit rights has taken place in accordance with what is stated in the prospectus that the Company published on March 30, 2021 due to the Rights Issue (the “Prospectus”). Notification of such allocation is announced separately by a settlement note sent out. Nominee-registered shareholders receive notification of allotment in accordance with instructions from the respective nominee.

Through the Rights Issue, the number of shares in the Company increase by 69,624,070 shares, from 62,661,667 shares to 132,285,737 shares and the share capital increase by SEK 6,266,166.30, from SEK 5,639,550.03 to SEK 11,905,716.33. In the event that all warrants are also fully exercised for subscription of new shares in the Company, the number of shares in the Company will increase with an additional maximum of 69,624,070 shares, from 132,285,737 shares to 201,909,807 shares, and the share capital will increase with an additional maximum SEK 6,266,166.30, from SEK 11,905,716.33 to SEK 18,171,882.63. Each warrant series 2021/2023 entitles the holder to subscribe for one (1) new share in the Company at an exercise price corresponding to seventy (70) percent of the volume-weighted average price of the Company's share on Spotlight Stock Market during the period from and including March 8, 2023 to and including March 21, 2023, however a minimum of SEK 0.09 and a maximum of SEK 1.22 per share.

The Extraordinary General Meeting on March 10, 2021, resolved to authorize the Board of Directors to resolve on the Over-Allotment Issue in order to satisfy any oversubscription in the Rights Issue. However, the outcome in the Rights Issue means that the Over-Allotment Issue will not be carried out.

Trading with BTU (Paid Subscribed Unit) takes place on Spotlight Stock Market until the conversion of BTU into shares and warrants after the Rights Issue has been registered with the Swedish Companies Registration Office. Registration with the Swedish Companies Registration Office is expected to take place during week 18, 2021.

In connection with the Rights Issue, a number of external investors have made underwriting commitments. For underwriting commitments made, underwriting compensation of 10 percent of the underwritten amount is paid in cash or alternatively 14 percent of the underwritten amount in the form of newly issued shares in the Company. Underwriters who wish to receive underwriting compensation in the form of newly issued shares must notify Mangold Fondkommission AB no later than April 29, 2021. The subscription price for any shares issued as underwriting compensation has been set at SEK 0.80 per share, which corresponds to the volume-weighted average share price for the Company's share on Spotlight Stock Market during the subscription period in the Rights Issue, April 8, 2021 until and including April 22, 2021. In total, a maximum of 9,869,211 new shares may be issued as underwriters compensation to the underwriters.

Advisor

Mangold Fondkommission AB is the financial advisor and Setterwalls Advokatbyrå AB is the legal advisor to WntResearch in connection with the Rights Issue.

For further information:

Anders Rabbe, acting CEO
Phone: +46 707 646 500
E-mail: anders.rabbe@wntresearch.com

This information is information that WntResearch AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on April 27, 2021.

About WntResearch

WntResearch is a biotech company in oncology that develops new therapies intended to prevent the metastatic process. The company's research is focused on studying the endogenous protein WNT5A, which in scientific studies has shown to affect tumor cells' ability to move and spread in the body. WntResearch drug candidate Foxy-5 is a peptide that mimics the function of WNT5A and is intended to reduce the mobility and spread of cancer cells thus preventing metastases from occurring. Although current cancer treatment has become more effective, there are no effective ways to prevent the onset of metastases that cause about 90 percent of all cancer-related deaths. Foxy-5 has a unique mechanism of action and has shown a good safety profile with few side effects in two Phase I clinical trials. The safety and efficacy of Foxy-5 are now being evaluated in the ongoing Phase 2 clinical trial NeoFox, in patients with stage II-III colon cancer.

WntResearch is listed on the Spotlight Stock Market. For more information, please visit: www.wntresearch.com